This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.
A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells. This approach addresses a major bottleneck in immunotherapy development and could accelerate the creation of personalized treatments.
The platform, called ATTACH (Assessment of T cells Tethered to Antigen Class I Histocompatibility), identifies the strongest interactions between T cells and cancer-specific proteins, isolating only the most effective, tumor-reactive T cells for further study and therapeutic use.
The study, published today in the Journal for ImmunoTherapy of Cancer, was led by Alexandre Reuben, Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology, and Amanda Montoya, senior research assistant in the Reuben lab.
Despite growing evidence of alcohol’s harms, it remains deeply embedded in social norms and cultural rituals, both in the US and abroad.
The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specializes or retains its stem cell properties. A team of researchers led by Professor Stefan H. Stricker, professor of epigenetic engineering at LMU’s Biomedical Center and research group leader at Helmholtz Munich, has worked with international partners to demonstrate directly for the first time that the amount of ribosomal RNA (rRNA) directly regulates these processes. Their results were published in the journal Science.
It has been established for some time that the amount of ribosomal RNA differs among different types of cells and is altered in a number of diseases. But it remained unclear whether these specific characteristics are the cause or merely the result of biological processes.
With the newly developed CRISPR-based method TAPIR (Targeted Activation of Protein Translation), researchers now have access to a tool that can boost the activity of ribosomal genes and, as a result, influence a cell’s protein production. “Our new study shows that targeted activation of rRNA production significantly increases protein synthesis,” explains Stricker, lead author of the publication.
RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene therapies to genome editing and synthetic biology. However, designing RNA molecules that reliably fold into a desired secondary structure remains a major challenge. Even for relatively short sequences, the number of possible nucleotide combinations grows exponentially, making it difficult to identify optimal candidates. As a result, conventional computational methods often require extensive candidate evaluations, creating a significant bottleneck when experimental validation is both time-consuming and costly.
To address this challenge, researchers from Keio University, led by Project Lecturer Shuta Kikuchi of the Graduate School of Science and Technology and Professor Shu Tanaka of the Department of Applied Physics and Physico-Informatics, developed a novel RNA inverse folding framework based on factorization machine with quadratic optimization annealing (FMQA). This machine learning– and Ising machine–driven black-box optimization approach is designed to identify high-quality RNA sequence candidates with relatively few evaluations.
“We investigated a new application of FMQA in biomolecular design, where its potential remains relatively unexplored. Since RNA, DNA and protein sequences are inherently categorical in nature, it is unclear how converting them into binary representations affects optimization performance. In this study, we examined RNA inverse folding and the influence of different encoding and assignment choices within FMQA,” says Dr. Kikuchi. The findings are published in Scientific Reports.
Valenti et al. used the MT bench assay to quantify FUS homotypic/heterotypic interactions in compartments of heterogeneous compositions in cells. They showed that FUS heterotypic interactions with other RBPs, orchestrated by its disease-related NLS, prevent FUS phase separation independently from nuclear transporters.
University of Louisville researchers have discovered how a naturally occurring microbial compound may help protect the gut and support future treatment strategies for inflammatory bowel disease (IBD).
IBD, which includes conditions such as Crohn’s disease and ulcerative colitis, affects millions of people worldwide. The disease is characterized by chronic inflammation and damage to the intestinal lining. A healthy gut barrier helps keep harmful bacteria from leaking out of the intestines while allowing nutrients to enter the body. In people with IBD, that barrier becomes weakened, leading to inflammation, pain and long-term complications.
A research team led by Venkatakrishna Rao Jala, associate professor in the Department of Microbiology and Immunology and UofL’s Brown Cancer Center, discovered how a naturally occurring microbial metabolite called urolithin A, or UroA, which is generated by gut bacteria after digestion of foods such as pomegranates, walnuts and berries, activates a protective pathway in the intestine that may help preserve gut health.
🧬 Benjamin Arya interviews me about my research on gene therapy delivery systems, about my first startup company Cathedral Therapeutics (see link to website and a bit about my newer venture towards solving the brain delivery problem.
“Putting an AAV inside of a protein vault shields the AAV from the preexisting antibodies that humans produce.”